SG11201705692SA - Modified hepatitis post-transcriptional regulatory elements - Google Patents
Modified hepatitis post-transcriptional regulatory elementsInfo
- Publication number
- SG11201705692SA SG11201705692SA SG11201705692SA SG11201705692SA SG11201705692SA SG 11201705692S A SG11201705692S A SG 11201705692SA SG 11201705692S A SG11201705692S A SG 11201705692SA SG 11201705692S A SG11201705692S A SG 11201705692SA SG 11201705692S A SG11201705692S A SG 11201705692SA
- Authority
- SG
- Singapore
- Prior art keywords
- regulatory elements
- transcriptional regulatory
- modified hepatitis
- hepatitis post
- post
- Prior art date
Links
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 230000001124 posttranscriptional effect Effects 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10041—Use of virus, viral particle or viral elements as a vector
- C12N2730/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562102569P | 2015-01-12 | 2015-01-12 | |
PCT/US2016/013109 WO2016115177A1 (en) | 2015-01-12 | 2016-01-12 | Modified hepatitis post-transcriptional regulatory elements |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201705692SA true SG11201705692SA (en) | 2017-08-30 |
Family
ID=55310922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201705692SA SG11201705692SA (en) | 2015-01-12 | 2016-01-12 | Modified hepatitis post-transcriptional regulatory elements |
Country Status (18)
Country | Link |
---|---|
US (1) | US10363269B2 (en) |
EP (1) | EP3245292B1 (en) |
JP (1) | JP6868560B2 (en) |
KR (1) | KR102554374B1 (en) |
CN (1) | CN107429260B (en) |
AU (1) | AU2016206868B2 (en) |
BR (1) | BR112017014917A2 (en) |
CA (1) | CA2973483A1 (en) |
ES (1) | ES2877367T3 (en) |
HK (1) | HK1246347A1 (en) |
IL (1) | IL253399B2 (en) |
MA (1) | MA41346A (en) |
MX (1) | MX2017009113A (en) |
MY (1) | MY187559A (en) |
RU (1) | RU2734594C2 (en) |
SA (1) | SA517381912B1 (en) |
SG (1) | SG11201705692SA (en) |
WO (1) | WO2016115177A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ769595A (en) | 2014-11-05 | 2023-06-30 | Juno Therapeutics Inc | Methods for transduction and cell processing |
AU2016301196B2 (en) | 2015-08-06 | 2022-09-08 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
MX2019004487A (en) | 2016-10-20 | 2020-02-07 | Sangamo Therapeutics Inc | Methods and compositions for the treatment of fabry disease. |
CN107058315B (en) * | 2016-12-08 | 2019-11-08 | 上海优卡迪生物医药科技有限公司 | Strike the siRNA for subtracting people PD-1, recombinant expression CAR-T carrier and its construction method and application |
JP7227912B2 (en) | 2017-02-08 | 2023-02-24 | ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド | Regulation of chimeric antigen receptors |
WO2019060425A1 (en) | 2017-09-19 | 2019-03-28 | Massachusetts Institute Of Technology | Compositions for chimeric antigen receptor t cell therapy and uses thereof |
CA3113618A1 (en) | 2018-09-28 | 2020-04-02 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
CN111825769B (en) * | 2019-04-16 | 2022-03-25 | 上海科技大学 | Ubiquitination-deleted chimeric antigen receptor and application thereof |
TW202115126A (en) | 2019-06-11 | 2021-04-16 | 美商舒爾人類基因療法公司 | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein |
US11642409B2 (en) | 2019-06-26 | 2023-05-09 | Massachusetts Insttute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
EP4048800A1 (en) | 2019-10-23 | 2022-08-31 | Shire Human Genetic Therapies, Inc. | Adeno-associated virus vectors based gene therapy for hereditary angioedema |
MX2022011080A (en) | 2020-03-10 | 2023-01-04 | Massachusetts Inst Technology | Methods for generating engineered memory-like nk cells and compositions thereof. |
JP2023517889A (en) | 2020-03-10 | 2023-04-27 | マサチューセッツ インスティテュート オブ テクノロジー | Compositions and methods for immunotherapy of NPM1c-positive cancers |
DE102020111571A1 (en) * | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES |
KR20230036061A (en) | 2020-04-27 | 2023-03-14 | 주노 쎄러퓨티크스 인코퍼레이티드 | Stabilization of polyethylenimine-deoxyribonucleic acid complex size and activity |
WO2021221783A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
US20210338833A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
KR20230043869A (en) | 2020-08-07 | 2023-03-31 | 스페이스크래프트 세븐, 엘엘씨 | Placophilin-2 (PKP2) gene therapy using AAV vectors |
KR20220035693A (en) * | 2020-09-14 | 2022-03-22 | 주식회사 제너로스 | Adeno-associated virus vector for targeted gene delivery |
US20220106614A1 (en) * | 2020-09-29 | 2022-04-07 | NeuExcell Therapeutics Inc. | Dlx2 vector |
EP4263614A1 (en) | 2020-12-16 | 2023-10-25 | Takeda Pharmaceutical Company Limited | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein |
US20230049217A1 (en) * | 2021-05-21 | 2023-02-16 | Novartis Ag | Compositions and methods for enhancing visual function |
WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
WO2023081803A2 (en) * | 2021-11-04 | 2023-05-11 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
WO2024077052A1 (en) * | 2022-10-04 | 2024-04-11 | Emergent Product Development Gaithersburg Inc. | Novel vsv virus formulations |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
AU4746590A (en) | 1988-12-28 | 1990-08-01 | Stefan Miltenyi | Methods and materials for high gradient magnetic separation of biological materials |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
DE69128037T2 (en) | 1990-11-13 | 1998-05-07 | Immunex Corp | BIFUNCTIONAL SELECTABLE FUSION GENES |
EP0804590A1 (en) | 1993-05-21 | 1997-11-05 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
FR2777909B1 (en) | 1998-04-24 | 2002-08-02 | Pasteur Institut | USE OF TRIPLEX-STRUCTURED DNA SEQUENCES FOR THE TRANSFER OF NUCLEOTID SEQUENCES IN CELLS, RECOMBINANT VECTORS CONTAINING THESE TRIPLEX SEQUENCES |
WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
US7262049B2 (en) | 1999-03-16 | 2007-08-28 | Dana-Farber Cancer Institute, Inc. | Pseudotyped lentiviral vectors and uses thereof |
CA2410510A1 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
US7419829B2 (en) | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
WO2002077029A2 (en) | 2000-11-07 | 2002-10-03 | City Of Hope | Cd19-specific redirected immune cells |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
CA2344208A1 (en) | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Method |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
US7384738B2 (en) | 2002-03-28 | 2008-06-10 | Bremel Robert D | Retrovirus-based genomic screening |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
EP2141997B1 (en) | 2007-03-30 | 2012-10-31 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
US8747290B2 (en) | 2007-12-07 | 2014-06-10 | Miltenyi Biotec Gmbh | Centrifuge for separating a sample into at least two components |
US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
JP5173594B2 (en) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | Management apparatus, image forming apparatus, and processing method thereof |
EP4049674A1 (en) | 2009-11-03 | 2022-08-31 | City of Hope | Truncated epidermal growth factor receptor (egfrt) for transduced t cell selection |
EP3305798A1 (en) | 2010-12-09 | 2018-04-11 | The Trustees of The University of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
CN106074601A (en) | 2011-03-23 | 2016-11-09 | 弗雷德哈钦森癌症研究中心 | Method and composition for cellular immunotherapy |
US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
EP2776451B1 (en) | 2011-11-11 | 2018-07-18 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
CA2872471C (en) | 2012-05-03 | 2022-11-22 | Fred Hutchinson Cancer Research Center | Enhanced affinity t cell receptors and methods for making the same |
RU2019126655A (en) | 2012-08-20 | 2019-11-12 | Фред Хатчинсон Кансэр Рисёч Сентер | Nucleic acids encoding chimeric receptors, polypeptide chimeric receptor encoded thereby, an expression vector containing them DEDICATED host cells containing them, a composition comprising an isolated host cells AND METHODS FOR ISOLATED CELLS OF HOST IN VITRO, METHODS FOR SELECTING NUCLEIC ACID ENCODING CHIMERIC RECEPTORS IN VITRO AND METHODS FOR CARRYING OUT CELL IMMUNOTHERAPY IN A SUBJECT HAVING A TUMOR |
CN112430580A (en) | 2012-10-02 | 2021-03-02 | 纪念斯隆-凯特琳癌症中心 | Compositions and methods for immunotherapy |
JP5372297B1 (en) | 2012-12-20 | 2013-12-18 | 三菱電機株式会社 | In-vehicle device and program |
KR20210108497A (en) | 2013-02-26 | 2021-09-02 | 메모리얼 슬로안 케터링 캔서 센터 | Compositions and methods for immunotherapy |
ES2831315T3 (en) | 2013-04-03 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | Effective Generation of Pluripotent Stem Cell Derived Tumor Targeted Cells |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
GB201318804D0 (en) | 2013-10-24 | 2013-12-11 | Adaptimmune Ltd | Vectors for transgene expression |
BR112016014156A8 (en) | 2013-12-20 | 2023-04-11 | Hutchinson Fred Cancer Res | TAGGED CHIMERIC EFFECTOR MOLECULES AND RECEPTORS THEREOF |
RU2752275C2 (en) | 2014-04-10 | 2021-07-26 | Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) | Method and compositions for cellular immunotherapy |
KR20160002030A (en) * | 2014-06-30 | 2016-01-07 | 성지산업 주식회사 | Object detection method using a Doppler sensor and Device |
NZ769595A (en) | 2014-11-05 | 2023-06-30 | Juno Therapeutics Inc | Methods for transduction and cell processing |
-
2016
- 2016-01-11 MA MA041346A patent/MA41346A/en unknown
- 2016-01-12 RU RU2017126975A patent/RU2734594C2/en active
- 2016-01-12 CA CA2973483A patent/CA2973483A1/en active Pending
- 2016-01-12 SG SG11201705692SA patent/SG11201705692SA/en unknown
- 2016-01-12 BR BR112017014917A patent/BR112017014917A2/en not_active Application Discontinuation
- 2016-01-12 MY MYPI2017001032A patent/MY187559A/en unknown
- 2016-01-12 EP EP16703392.7A patent/EP3245292B1/en active Active
- 2016-01-12 JP JP2017536779A patent/JP6868560B2/en active Active
- 2016-01-12 MX MX2017009113A patent/MX2017009113A/en unknown
- 2016-01-12 WO PCT/US2016/013109 patent/WO2016115177A1/en active Application Filing
- 2016-01-12 KR KR1020177022738A patent/KR102554374B1/en active IP Right Grant
- 2016-01-12 AU AU2016206868A patent/AU2016206868B2/en active Active
- 2016-01-12 CN CN201680015106.6A patent/CN107429260B/en active Active
- 2016-01-12 ES ES16703392T patent/ES2877367T3/en active Active
- 2016-01-12 US US14/994,114 patent/US10363269B2/en active Active
-
2017
- 2017-07-10 IL IL253399A patent/IL253399B2/en unknown
- 2017-07-12 SA SA517381912A patent/SA517381912B1/en unknown
-
2018
- 2018-05-03 HK HK18105704.6A patent/HK1246347A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2017126975A (en) | 2019-02-20 |
US20160199412A1 (en) | 2016-07-14 |
AU2016206868A1 (en) | 2017-07-27 |
EP3245292A1 (en) | 2017-11-22 |
RU2017126975A3 (en) | 2019-09-04 |
AU2016206868B2 (en) | 2022-03-17 |
ES2877367T3 (en) | 2021-11-16 |
JP6868560B2 (en) | 2021-05-12 |
US10363269B2 (en) | 2019-07-30 |
BR112017014917A2 (en) | 2018-03-13 |
CN107429260B (en) | 2021-12-31 |
CN107429260A (en) | 2017-12-01 |
WO2016115177A1 (en) | 2016-07-21 |
EP3245292B1 (en) | 2021-06-09 |
CA2973483A1 (en) | 2016-07-21 |
HK1246347A1 (en) | 2018-09-07 |
MY187559A (en) | 2021-09-29 |
JP2018502583A (en) | 2018-02-01 |
SA517381912B1 (en) | 2021-12-30 |
RU2734594C2 (en) | 2020-10-20 |
IL253399B2 (en) | 2023-06-01 |
MX2017009113A (en) | 2017-11-15 |
MA41346A (en) | 2017-11-21 |
IL253399A0 (en) | 2017-09-28 |
KR20170131362A (en) | 2017-11-29 |
KR102554374B1 (en) | 2023-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1246347A1 (en) | Modified hepatitis post-transcriptional regulatory elements | |
HRP20190442T1 (en) | Capsid | |
IL256063A (en) | Autoinjector | |
GB201504223D0 (en) | Biallelic genetic modification | |
GB201501118D0 (en) | Pellicle | |
GB201406608D0 (en) | Virus | |
IL259010A (en) | Chimeric post-transcriptional regulatory element | |
GB201517368D0 (en) | Value | |
GB201419572D0 (en) | Virus | |
HUE051749T2 (en) | Regulatory elements from labyrinthulomycetes microorganisms | |
IL257653A (en) | Norovirus vaccine | |
PL3377148T3 (en) | Autoinjector | |
GB201518940D0 (en) | Novel safe | |
GB2535632B (en) | Stroller | |
GB2588720B (en) | Stroller | |
GB201522707D0 (en) | Pallet arrangement | |
GB201509839D0 (en) | One piece | |
GB201502617D0 (en) | Supports | |
GB201809261D0 (en) | Stroller | |
GB201522013D0 (en) | Virus | |
GB201516936D0 (en) | Virus | |
GB201507419D0 (en) | Virus | |
GB201506357D0 (en) | Pallet | |
GB201600380D0 (en) | Modified virus | |
GB201503457D0 (en) | Pallet |